Quillivant Xr(Methylphenidate Hcl)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$188K
Medicare cost, 2024
$188K
Medicare cost, 2024
Medicare drug plans spent $188,309 on Quillivant Xr (methylphenidate hcl) in 2024, for 308 prescriptions and refills filled by 58 patients. Texas accounts for the most spending ($14,015, 7% of the total).
Medicare cost, 2024
$188K
-4.1% from 2023
Prescriptions
308
$611.39 per claim
Patients
58
73 prescribers
Total spending, 2024
$188K
$3,246.71 per patient
Questions and answers
How much does Medicare spend on Quillivant Xr?
Medicare prescription drug plans paid $188K for Quillivant Xr in 2024, for 308 prescriptions and refills to 58 patients (down 4.1% from 2023). The average cost per claim was $611.39.
Which state spends the most on Quillivant Xr?
Texas had the highest Medicare cost for Quillivant Xr in 2024: $14K for 20 claims, followed by Ohio ($12K).
Who prescribes Quillivant Xr the most?
John-Paul Gomez, psychiatry in Bethlehem, PA, had the highest Medicare cost for Quillivant Xr in 2024: 11 claims costing $10K.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Quillivant Xr was $188K in 2024, after a high of $196K in 2023.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Quillivant Xr, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| John-Paul Gomez Bethlehem, PA | Psychiatry | 11 | Under 11 | $10K |
| Saira Mushtaq Houston, TX | Psychiatry | 12 | Under 11 | $9,650 |
| Paige N McInerney Augusta, ME | Psychiatry | 13 | Under 11 | $9,334 |
| Raul Manuel B Cruz Olympia, WA | Pulmonary Disease | 11 | Under 11 | $8,033 |
| Marie A Maugans-Coleman Hutchinson, KS | Certified Clinical Nurse Specialist | 12 | Under 11 | $7,616 |
| Ann M Corey Meridian, ID | Nurse Practitioner | 13 | Under 11 | $3,897 |
| David A Ngo San Jose, CA | Psychiatry | 11 | Under 11 | $3,438 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 62 | 244 | 51 | $160K |
| 2023 | 84 | 313 | 64 | $196K |
| 2024 | 73 | 308 | 58 | $188K |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Tris Pharma Inc | 308 | $188K |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 4
- RxNorm concept IDs
- 1312583, 1312589
- Application numbers
- NDA202100
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 60,702 side-effect reports named methylphenidate hydrochloride, the active ingredient of Quillivant Xr (reports from 2003 on). 37,008 of them (61.0%) were serious, 2,752 named a death and 12,393 named a hospital stay. The reactions named most often were drug ineffective, fatigue and nausea. 17,492 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
60,702
3,799 in 2025 (+2.5% from 2024)
Serious
61.0%
37,008 reports
Deaths named
2,752
4.5% of reports
Hospital stays
12,393
20.4% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Quillivant Xr?
60,702 reports from 2003 through September 2026 named methylphenidate hydrochloride, the active ingredient of Quillivant Xr. 37,008 of them (61.0%) were serious, 2,752 named a death and 12,393 named a hospital stay.
What are the most reported side effects of Quillivant Xr?
6,255 reports named drug ineffective, the reaction named most often, followed by fatigue (3,258) and nausea (3,056). In the last 5 years the reaction named most often was drug ineffective (2,250 reports). A report can name several reactions.
How many side-effect reports named Quillivant Xr in 2025?
3,799 reports were received in 2025 (+2.5% from 2024). 2026 so far: 2,837 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Quillivant Xr caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Quillivant Xr caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with methylphenidate hydrochloride: Concerta, Ritalin, Ritalin La, Quillichew Er, Relexxii, Methylin
- Makers on the stock market:
4507.T
JNJ·4507.T drug pipeline - Drug approvals (7 approvals on file for methylphenidate hydrochloride) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (methylphenidate hydrochloride) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.